150 related articles for article (PubMed ID: 19708980)
1. Hyperhomocysteinemia in uremia--a red flag in a disrupted circuit.
Perna AF; Ingrosso D; Violetti E; Luciano MG; Sepe I; Lanza D; Capasso R; Ascione E; Raiola I; Lombardi C; Stenvinkel P; Massy Z; De Santo NG
Semin Dial; 2009; 22(4):351-6. PubMed ID: 19708980
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics in hyperhomocysteinemic states. A special focus on uremia.
Ingrosso D; Perna AF
Biochim Biophys Acta; 2009 Sep; 1790(9):892-9. PubMed ID: 19245874
[TBL] [Abstract][Full Text] [Related]
3. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
[TBL] [Abstract][Full Text] [Related]
4. Hyperhomocysteinemia: an additional cardiovascular risk factor.
Fanapour PC; Yug B; Kochar MS
WMJ; 1999 Dec; 98(8):51-4. PubMed ID: 10639897
[TBL] [Abstract][Full Text] [Related]
5. Is homocysteine toxic in uremia?
Perna AF; Luciano MG; Pulzella P; Satta E; Capasso R; Lombardi C; Ingrosso D; De Santo NG
J Ren Nutr; 2008 Jan; 18(1):12-7. PubMed ID: 18089438
[TBL] [Abstract][Full Text] [Related]
6. The methionine-homocysteine cycle and its effects on cognitive diseases.
Miller AL
Altern Med Rev; 2003 Feb; 8(1):7-19. PubMed ID: 12611557
[TBL] [Abstract][Full Text] [Related]
7. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin.
Perna AF; Castaldo P; Ingrosso D; De Santo NG
J Nephrol; 1999; 12(4):230-40. PubMed ID: 10493566
[TBL] [Abstract][Full Text] [Related]
8. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
Gonin JM; Nguyen H; Gonin R; Sarna A; Michels A; Masri-Imad F; Bommareddy G; Chassaing C; Wainer I; Loya A; Cary D; Barker LF; Assefi A; Greenspan R; Mahoney D; Wilcox CS
J Nephrol; 2003; 16(4):522-34. PubMed ID: 14696754
[TBL] [Abstract][Full Text] [Related]
9. Homocysteine in uremia.
Perna AF; Ingrosso D; Lombardi C; Cesare CM; Acantora F; Satta E; De Santo NG
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S123-6. PubMed ID: 12612968
[TBL] [Abstract][Full Text] [Related]
10. [Hyperhomocysteinemia as a vascular risk factor in chronic hemodialysis patients].
Trimarchi H; Young P; Díaz ML; Schropp J; Forrester M; Freixas E
Medicina (B Aires); 2005; 65(6):513-7. PubMed ID: 16433478
[TBL] [Abstract][Full Text] [Related]
11. [Homocysteine. The cardiovascular risk factor of the next millennium?].
Suárez García I; Gómez Cerezo JF; Ríos Blanco JJ; Barbado Hernández FJ; Vázquez Rodríguez JJ
An Med Interna; 2001 Apr; 18(4):211-7. PubMed ID: 11496543
[TBL] [Abstract][Full Text] [Related]
12. New cardiovascular risk factors: homocysteine and vitamins involved in homocysteine metabolism.
De Caterina R; Zampolli A; Madonna R; Fioretti P; Vanuzzo D
Ital Heart J; 2004 Jun; 5 Suppl 6():19S-24S. PubMed ID: 15185912
[TBL] [Abstract][Full Text] [Related]
13. [Homocysteine and hyperhomocysteinemia].
Laskowska-Klita T
Pol Merkur Lekarski; 2001 Mar; 10(57):135-7. PubMed ID: 11398509
[TBL] [Abstract][Full Text] [Related]
14. Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients.
Suliman ME; Lindholm B; Bárány P; Qureshi AR; Stenvinkel P
Semin Dial; 2007; 20(6):523-9. PubMed ID: 17991198
[TBL] [Abstract][Full Text] [Related]
15. Hyperhomocysteinemia: clinical and therapeutical involvement in venous thrombosis.
Hoţoleanu C; Porojan-Iuga M; Rusu ML; Andercou A
Rom J Intern Med; 2007; 45(2):159-64. PubMed ID: 18333369
[TBL] [Abstract][Full Text] [Related]
16. Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care.
Booth GL; Wang EE
CMAJ; 2000 Jul; 163(1):21-9. PubMed ID: 10920726
[TBL] [Abstract][Full Text] [Related]
17. [Homocysteine metabolism and risk of cardiovascular diseases: importance of the nutritional status on folic acid, vitamins B6 and B12].
Alemán G; Tovar AR; Torres N
Rev Invest Clin; 2001; 53(2):141-51. PubMed ID: 11421110
[TBL] [Abstract][Full Text] [Related]
18. Toxic effects of hyperhomocysteinemia in chronic renal failure and in uremia: cardiovascular and metabolic consequences.
Perna AF; Capasso R; Acanfora F; Satta E; Lombardi C; Ingrosso D; Violetti E; Romano MM; De Santo NG
Semin Nephrol; 2006 Jan; 26(1):20-3. PubMed ID: 16412820
[TBL] [Abstract][Full Text] [Related]
19. [Consequences of moderate hyperhomocysteinemia in internal medicine].
Zák A; Zeman M
Cas Lek Cesk; 2004; 143(6):367-74. PubMed ID: 15309862
[TBL] [Abstract][Full Text] [Related]
20. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events.
Vianna AC; Mocelin AJ; Matsuo T; Morais-Filho D; Largura A; Delfino VA; Soares AE; Matni AM
Hemodial Int; 2007 Apr; 11(2):210-6. PubMed ID: 17403173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
